<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01854437</url>
  </required_header>
  <id_info>
    <org_study_id>1391</org_study_id>
    <nct_id>NCT01854437</nct_id>
  </id_info>
  <brief_title>The Effect of Magnesium Oxide on Plasma Phosphate in Hemodialysis Patients</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shiraz University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shiraz University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hyperphosphatemia is a common problem in hemodialysis (HD) patients. Different chelators for
      control of Hyperphosphatemia are used. The aim of this study was to assess the effect of
      magnesium oxide (Mg Oxide) on the control of serum phosphorus (P) level and evaluation of its
      side effects in hemodialysis patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>4 Months</target_duration>
  <primary_outcome>
    <measure>plasma phosphate level</measure>
    <time_frame>4 week</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">42</enrollment>
  <condition>Hyperphosphatemia</condition>
  <arm_group>
    <arm_group_label>Mg Oxide</arm_group_label>
    <description>Mg Oxide (Mg速, 21st Century速) 250 mg orally for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <description>placebo 1 tab TDS</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mg Oxide</intervention_name>
    <description>250 mg orally for 4 weeks</description>
    <arm_group_label>Mg Oxide</arm_group_label>
    <other_name>(Mg速, 21st Century速)</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        hemodialysis patients
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        hemodialysis with duration&gt;3 months serum P level &gt;5.5 mg/dl serum Ca&gt;8 mg/dl.

        Exclusion Criteria:

        Mg level &gt;3 mg/dl
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Shiraz University Hemodialysis Center</name>
      <address>
        <city>Shiraz</city>
        <state>Fars</state>
        <zip>o98-711</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <link>
    <url>http://www.pubmed.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 4, 2013</study_first_submitted>
  <study_first_submitted_qc>May 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2013</study_first_posted>
  <last_update_submitted>May 12, 2013</last_update_submitted>
  <last_update_submitted_qc>May 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shiraz University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Maryam Pakfetrat</investigator_full_name>
    <investigator_title>associated professor of shiraz Shiraz University of Medical Sciences</investigator_title>
  </responsible_party>
  <keyword>mg oxide</keyword>
  <keyword>hyperphosphatemia</keyword>
  <keyword>plasma phosphor level</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperphosphatemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

